Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

There are no transmission terms in the subcorpus


Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page




    Thrombotic microvascular injury is not mediated by thrombotic microangiopathy MESHD despite systemic complement activation in Covid-19 patients

    Authors: Adrien De Voeght; Doriane Calmes; Floran Beck; Jean-Baptiste Sylvestre; Philippe Delvenne; Pierre Peters; Gaelle Vertenoeil; Frederic Baron; Nathalie Layios; Jean-Luc Canivet

    doi:10.1101/2020.06.18.20115873 Date: 2020-06-22 Source: medRxiv

    Hypoxemia HP and coagulopathy are common in severe symptomatic patients of coronavirus disease MESHD 2019 (COVID-19). Histological evidence shows implication of complement activation and lung injury MESHD. We research sign of complement activation and presence of thrombotic microangiopathy MESHD in 8 severe patients. Six of them presented moderate elevation of final pathway of complement / sC5b-9 (median value : 350 ng/mL [IQR : 300,5-514,95 ng/mL]). Two patients have been autopsied and presence of thrombotic microvascular injury have been found. Interestingly, none the 8 patients had signs of mechanical hemolytic anemia MESHD hemolytic anemia HP (median value of hemoglobin : 10,5 gr/dL[IQR : 8,1-1,9], median value of haptoglobuline 4,49 [IQR 3,55-4,66], none of the patients has schistocyte) and thrombocytopenia MESHD thrombocytopenia HP (median value: 348000/mL [IQR : 266 000-401 000). Finally, all 8 patients had elevated d-dimer (median value : 2226 microgr/l [IQR : 1493- 2362]) and soluble fibrin monomer complex (median value : 8.5 mg/mL, IQR[ <6-10.6]). In summary, this study show moderate activation of complement and coagulation with presence of thrombotic microvascular injury in patients with severe COVID-19 without evidence of systemic thrombotic microangiopathy MESHD.

    COVID-19 Infection MESHD Associated With Auto-immune Hemolytic Anemia MESHD Hemolytic Anemia HP

    Authors: Antoine Capes; Sarah Bailly; Philippe Hantson; Ludovic Gerard; Pierre-François Laterre

    doi:10.21203/rs.3.rs-33157/v1 Date: 2020-06-02 Source: ResearchSquare

    A 62-y-old man developed Covid-19 infection MESHD. Fourteen days after the first respiratory symptoms, he presented biological signs of hemolysis MESHD with cold agglutinins 1/16384. Other causes of auto-immune hemolytic anemia MESHD hemolytic anemia HP (infectious, hematological,…) were excluded.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.